Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin.Metabolism. 1985; 34: 642-650
- Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice.Neth J Med. 2004; 62: 229-234
- Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial.Arch Intern Med. 1994; 154: 1586-1595
- The safety of over-the-counter niacin.BMC Clin Pharmacol. 2003; 3: 4-11
- Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.Proc Natl Acad Sci U S A. 2006; 103: 6682-6687
- Discovery of a potent and selective prostaglandin D(2) receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).J Med Chem. 2007; 50: 794-806
- Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.Am J Cardiol. 2008; 101: 625-630
- Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.Int J Clin Pract. 2008; 62: 1959-1970
- Validation of a questionnaire to assess niacin-induced cutaneous flushing.Curr Med Res Opin. 2007; 23: 1549-1560
This study was funded by Merck Sharp & Dohme, Corporation, a subsidiary of Merck & Company, Incorporated (Whitehouse Station, New Jersey).
Drs. Chen, Maccubbin, Kher, and Mitchel and J. Weimer Anderson, BS, W. Sirah, BS, and C. McCrary Sisk, BS, were current employees of Merck Sharp & Dohme at the time of the study and may hold stock/stock options in the company. Drs. Olsson and Bays were investigators in this study and have received research grants and honoraria from Merck Sharp & Dohme . Dr. Olsson has received support for clinical trials from Amgen (Thousand Oaks, California), AstraZeneca (Wilmington, Delaware), Karo Bio (Huddinge, Sweden), MSD (Europe), Inc. (Brussels, Belgium), Pfizer (Collegeville, Pennsylvania), Roche (Basle, Switzerland), and Sanofi-Aventis (Paris, France) and has also received consultation fees from AstraZeneca, Karo Bio, Merck, Pfizer, and Roche.